



**Inion Oy**  
**(“Inion or “the Company”)**

**Payment of Non-Executive Directors’ Fees in Shares**

**Tampere, Finland and Guildford, UK. 13 June 2008...**Inion [LSE: IIN.L], a company focused on the development of novel biodegradable medical implants, announces that its Non-Executive Directors have received Inion shares in lieu of 50% of their directors’ fees in respect of the quarter ended 31 March 2008. This is part of a share-based payment scheme previously announced on 8 October 2007.

The share price used to calculate the number of shares issued to each Director was 18.5p, representing the closing mid-market share price on 31 March 2008, the last working day of the first quarter of 2008.

Non-Executive Director	No. of ordinary shares of EUR 0.03 issued	Share price (p)	Total shareholding following issue	% of current issued share capital
Göran Ando	33,784	18.5	160,187	0.21
David Anderson	20,270	18.5	51,112	0.07
Jim Beery	21,959	18.5	55,372	0.07
Peter Jensen	23,649	18.5	59,631	0.08
Markku Silén	21,959	18.5	55,372	0.07

-Ends-

**For further information, please contact:**

**Inion Oy**

Chris Lee, Chief Executive Officer  
Julien Cotta, Chief Financial Officer

Tel: +44 (0)1483 685390

**Citigate Dewe Rogerson**

Mark Swallow / David Dible

Tel: +44 (0)207 638 9571

**About Inion** ([www.inion.com](http://www.inion.com))

Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable and bioactive surgical implants in selected high value orthopaedic market segments.

Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima™ family of

biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation

Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation.

Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The Company has offices in the UK and USA, and its head office, R&D and production facilities are in Tampere, Finland.

*This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.*